V. Georgoulias - Concepedia

Author

V. Georgoulias

Also Known As

Angela George, Aristotelis Bamias, Judy Garber, Mia M. Gaudet, Patricia A. Ganz, Simon A. Gayther, V Georgoulias, V. GEORGOULIAS, V. Georgoulias, VASSILIOS GEORGOULIAS

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Heraklion University of Crete Heidelberg University German Cancer Research Center Metaxa Hospital

About

V. Georgoulias is an author at University Hospital of Heraklion specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	1.1K
2	Health Sciences	4	4	177
3	Cell Biology	3	3	168
4	Public Health	2	2	46
5	Biostatistics	2	2	46

V. Georgoulias

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat, Kyriaki Michailidou, Joe Dennis, The American Journal of Human Genetics	2018	1.1K
Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study Michael I. Koukourakis, George Kyrias, S. Kakolyris, Journal of Clinical Oncology	2000	272
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy Sophia Koukouraki, Ludwig G. Strauss, V. Georgoulias, European Journal of Nuclear Medicine and Molecular Imaging OncologyMedicineNeuroendocrine DisorderMetastatic Neuroendocrine TumoursPharmacotherapy	2006	152
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Alexandra Giatromanolaki, Michael I. Koukourakis, S. Kakolyris, PubMed Tumor BiologyWild-type P53AngiogenesisVegf GeneMedicine	1998	130
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy Sophia Koukouraki, Ludwig G. Strauss, V. Georgoulias, European Journal of Nuclear Medicine and Molecular Imaging MedicinePharmacologyNeuroendocrine DisorderMetastatic Neuroendocrine TumoursRadiopharmaceutical Therapy	2006	124
Continuation of Trastuzumab Beyond Disease Progression Is Feasible and Safe in Patients with Metastatic Breast Cancer: A Retrospective Analysis of 80 Cases by the Hellenic Cooperative Oncology Group George Fountzilas, Evangelia Razis, D. Tsavdaridis, Clinical Breast Cancer Metastatic Breast CancerOncologyBreast OncologyCancer ManagementRetrospective Analysis	2003	105
Combined role of tumor angiogenesis,bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma Alexandra Giatromanolaki, George P. Stathopoulos, Eleni Tsiobanou, Cancer	1999	92
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using68Ga-DOTATOC PET and comparison with18F-FDG PET Antonia Dimitrakopoulou‐Strauss, V. Georgoulias, Michael Eisenhut, European Journal of Nuclear Medicine and Molecular Imaging Sstr2 ExpressionMedicineComparison With18f-fdg PetPathologyBronchial Neoplasm	2006	78
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer Ioannis Gioulbasanis, Athanasios Pallis, Panagiotis J. Vlachostergios, Lung Cancer Metastatic Lung CancerPrognostic BiomarkersPrognostic EvaluationMedicineCancer Management	2012	61
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang, Annals of Oncology Antifibrotic TherapyFortis-m TrialMedicineMetronomic TherapyPharmacology	2013	55

Page 1